Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, announced that the article Polymer-Free Corticosteroid Dimer Implants for Controlled and Sustained Drug Delivery was recently published in Nature Communications. The article describes Ripple's Epidel™ technology platform which is founded on a discovery that drugs can be engineered into drug delivery implants without the use of polymers or excipients.